Treatment strategies in low-volume metastatic castration-resistant prostate cancer

Xiao X. Wei, Eric C. Ko, Charles J. Ryan

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Purpose of review There are currently limited data to guide the optimal management of patients with low-volume metastatic castration-resistant prostate cancer (mCRPC). In this review, we critically assess the most relevant clinical data, and discuss opportunities for advancing therapeutic options in this patient population. Recent findings Over the past decade, treatment options for mCRPC have expanded beyond taxanes to include abiraterone/prednisone, enzalutamide, sipuleucel-T, and radium-223. However, only a subset of patients in the landmark phase 3 studies would meet criteria consistent with low-volume mCRPC, and optimal treatment approach for this patient population is unclear. There is emerging evidence that mCRPC patients who harbor low-volume or indolent disease may derive the most benefit from immunotherapy. Whereas prospective data are lacking, stereotactic body radiation appears to be well tolerated and effective for local control of metastases in oligometastatic CRPC. Summary Prospective studies are needed to establish optimal therapeutic approaches in carefully selected low-volume mCRPC patients. Advances in functional imaging and molecular profiling should provide opportunities to optimize patient selection for effective treatment strategies.

Original languageEnglish (US)
Pages (from-to)596-603
Number of pages8
JournalCurrent Opinion in Urology
Issue number6
StatePublished - Nov 1 2017
Externally publishedYes


  • castration resistant
  • oligometastasis
  • prostate cancer
  • radiation therapy
  • systemic therapy


Dive into the research topics of 'Treatment strategies in low-volume metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this